Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

Authors Information
Article Notes and Dates
To Cite : Abbas Z, Tayyab G N, Qureshi M, Memon M S, Subhan A, et al. Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin, Hepat Mon. 2013 ;13(12):e14146. doi: 10.5812/hepatmon.14146.
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13(17): 2436-41
  • 2. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74[DOI][PubMed]
  • 3. Gonzalez SA, Keeffe EB. Management of chronic hepatitis C treatment failures: role of consensus interferon. Biologics. 2009; 3: 141-50[PubMed]
  • 4. Horoldt B, Haydon G, O'Donnell K, Dudley T, Nightingale P, Mutimer D. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver Int. 2006; 26(6): 650-9[DOI][PubMed]
  • 5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55(2): 245-64[DOI][PubMed]
  • 6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286): 958-65[PubMed]
  • 7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
  • 8. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5): 346-55[PubMed]
  • 9. Keeffe EB. Chronic hepatitis C: management of treatment failures. Clin Gastroenterol Hepatol. 2005; 3(10 Suppl 2)-5[PubMed]
  • 10. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology. 2009; 136(5): 1618-28 e2[DOI][PubMed]
  • 11. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009; 150(8): 528-40[PubMed]
  • 12. Camma C, Cabibbo G, Bronte F, Enea M, Licata A, Attanasio M, et al. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. J Hepatol. 2009; 51(4): 675-81[DOI][PubMed]
  • 13. Lim JK, Imperial JC, Keeffe EB. Retreatment of chronic hepatitis C virus infection. Rev Gastroenterol Disord. 2004; 4(3): 97-103[PubMed]
  • 14. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996; 16(7): 489-99[PubMed]
  • 15. Alavian SM, Behnava B, Tabatabaei SV. Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2010; 66(11): 1071-9[DOI][PubMed]
  • 16. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res. 1992; 12(1): 55-9[PubMed]
  • 17. Witthoft T. Review of consensus interferon in the treatment of chronic hepatitis C. Biologics. 2008; 2(4): 635-43[PubMed]
  • 18. Miglioresi L, Bacosi M, Russo F, Patrizi F, Saccenti P, Ursitti A, et al. Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. Hepatol Res. 2003; 27(4): 253-259[PubMed]
  • 19. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology. 1998; 27(4): 1136-43[DOI][PubMed]
  • 20. Barbaro G, Barbarini G. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. Eur J Gastroenterol Hepatol. 2002; 14(5): 477-83[PubMed]
  • 21. Moskovitz DN, Manoharan P, Heathcote EJ. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gastroenterol. 2003; 17(8): 479-82[PubMed]
  • 22. da Silva LC, Bassit L, Ono-Nita SK, Pinho JR, Nishiya A, Madruga CL, et al. High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study. J Gastroenterol. 2002; 37(9): 732-6[DOI][PubMed]
  • 23. Alaimo G, Di Marco V, Ferraro D, Di Stefano R, Porrovecchio S, D'Angelo F, et al. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial. World J Gastroenterol. 2006; 12(42): 6861-4[PubMed]
  • 24. Bocher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, et al. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int. 2006; 26(3): 319-25[DOI][PubMed]
  • 25. Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol. 2006; 44(2): 291-301[DOI][PubMed]
  • 26. Kaiser S, Hass HG, Gregor M. Successful retreatment of interferon/ribavirin nonresponders with daily dosing of consensus interferon. J Hepatol. 2005; 42: 207-208
  • 27. Jafri W, Subhan A. Hepatitis C in Pakistan: magnitude, genotype, disease characteristics and therapeutic response. Trop Gastroenterol. 2008; 29(4): 194-201[PubMed]
  • 28. Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, et al. Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol. 2009; 81(7): 1189-97[DOI][PubMed]
  • 29. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2): 289-93[DOI][PubMed]
  • 30. U.S. Department of Health and Human Services NIoH , National Cancer Institute . Common Terminology Criteria for Adverse Events v4.03 (CTCAE)..
  • 31. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(4): 1433-44[DOI][PubMed]
  • 32. Fattovich G, Zagni I, Minola E, Felder M, Rovere P, Carlotto A, et al. A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J Hepatol. 2003; 39(5): 843-9[PubMed]
  • 33. Bacon BR, Shiffman ML, Mendes F, Ghalib R, Hassanein T, Morelli G, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009; 49(6): 1838-46[DOI][PubMed]
  • 34. Moore CM, George M, Van Thiel DH. Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin. Dig Dis Sci. 2011; 56(10): 3032-7[DOI][PubMed]
  • 35. Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, et al. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. Dig Dis Sci. 2011; 56(8): 2439-48[DOI][PubMed]
  • 36. Leevy CB. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig Dis Sci. 2008; 53(7): 1961-6[DOI][PubMed]
  • 37. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology. 2002; 36(5 Suppl 1)-34[DOI][PubMed]
  • 38. Mangia A. Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. Liver Int. 2011; 31(1): 36-41[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check